medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-14-56-60medsovet-2652Research ArticleФУНКЦИОНАЛЬНЫЕ ЗАБОЛЕВАНИЯ КИШЕЧНИКАFUNCTIONAL BOWEL DISEASEПробиотики: концепция новая или старая?Probiotics: a new or an old concept?ЗахаренкоС. М.ZakharenkoS. M.

к.м.н., доцент, заместитель начальника кафедры инфекционных болезней (с курсом медицинской паразитологии и тропических заболеваний),

Санкт-Петербург

St. Petersburg

Федеральное государственное бюджетное военное образовательное учреждение высшего образования «Военно-медицинская академия им. С.М. Кирова» Министерства обороны Российской ФедерацииРоссияKirov Military Medical Academy, Federal State Budget Military Educational Institution of Higher Education of the Ministry of Defence of the Russian FederationRussian Federation2018091020180145660Copyright © Захаренко С.М., 20182018Захаренко С.М.Zakharenko S.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2652

Пробиотики представляют собой возобновляемый извне агент, способный осуществлять доставку активных факторов (метаболитов, регуляторных молекул и т.п.) к таргетным точкам желудочно-кишечного тракта и обеспечивать формирование источника регуляторных воздействий для внекишечных эффектов (таргетных точек). Уникальность пробиотиков заключается в том, что микробная клетка является одновременно собственно транспортным контейнером, системой доставки с обеспечением специфического распределения в желудочно-кишечном тракте и фабрикой воспроизводства эффекторных молекул.

Современная концепция «Пробиотики 2.0» подразумевает не только разработку биоинженерных штаммов, но и применение пробиотиков по максимально доказанным показаниям. Проводятся исследования в наиболее перспективных областях применения пробиотиков и формируется доказательная база для конкретного штамма по относительно узкому спектру клинически значимых эффектов. Примером служит штамм Bifidobacterium longum longum 35624®, зарегистрированный для уменьшения проявлений синдрома раздраженного кишечника. Однако не менее значимы и «старые» пробиотики, особенно в случае высокого соответствия оригинального штамма «10 золотым правилам пробиотической терапии». 

Probiotics are an agent renewable from the outside that is capable of delivering active factors (metabolites, regulatory molecules, etc.) to target points of the gastrointestinal tract, and ensure the formation of a regulatory impact source for extraintestinal effects (target points). The uniqueness of probiotics lies in the fact that the microbial cell is simultaneously a proper transport container, a delivery system with a specific distribution in the gastrointestinal tract and a factory for reproduction of effector molecules.

The modern Probiotics 2.0 concept implies not only the development of bioengineering strains, but the use of probiotics for the maximally proven indications. Conducting research in the most promising areas of probiotics usage, on the one hand, and the development of evidence base for a particular strain in a relatively narrow spectrum of clinically significant effects, on the other hand, significantly reduces the financial and time costs to bring new products to market. An example is a strain of Bifidobacterium longum longum 35624® that was authorized for the treatment of patients with irritable bowel syndrome. However, the “old” probiotics are no less important, especially if the original strain compliance with the “10 golden rules for probiotic therapy” is high.

пробиотикиBifidobacterium longum longum 35624S. BoulardiiprobioticBifidobacterium longum longum 35624S. boulardiiReferencesNIH Human Microbiome Project. https://www.hmpdacc.org.NIH Human Microbiome Project. https://www.hmpdacc.org.MetaHIT Project. http://www.metahit.eu/.MetaHIT Project. http://www.metahit.eu/.Human Metabolome Project. http://www.hmdb.ca.Human Metabolome Project. http://www.hmdb.ca.Ардатская М.Д., Бельмер С.В., Добрица В.П., Захаренко С.М., Лазебник Л.Б., Минушкин О.Н., Орешко Л.С., Ситкин С.И., Ткаченко Е.И., Суворов А.Н., Хавкин А.И., Шендеов Б.А. Дисбиоз (дисбактериоз) кишечника: современное состояние проблемы, комплексная диагностика и лечебная коррекция. Экспериментальная и клиническая гастроэнтерология, 2015, 117(5): 13-50.Ardatskaya MD, Belmer SV, Dobritsa VP, Zakharenko SM, Lazebnik LB, Minushkin ON, Oreshko LS, Sitkin SI, Tkachenko EI, Suvorov AN, Khavkin AI, Shendeov BA. Dysbiosis (dysbacteriosis) of the intestine: the current state of the problem, complex diagnosis and therapeutic correction. Eksperimentalnaya i Klinicheskaya Gastroehnterologiya, 2015, 117 (5): 13-50.Hall E, Bernhardt E, Bier R, Bradford M, Boot C, Cotner J, del Giorgio P, Evans S, Graham E, Jones S, Lennon J, Locey K, Nemergut D, Osborne B, Rocca J, Schimel J, Wallenstein M. Understanding How Microbiomes Influence the Systems they Inhabit: Moving from a correlative to a causal research framework. bioRxiv 065128, doi: https://doi.org/10.1101/065128.Hall E, Bernhardt E, Bier R, Bradford M, Boot C, Cotner J, del Giorgio P, Evans S, Graham E, Jones S, Lennon J, Locey K, Nemergut D, Osborne B, Rocca J, Schimel J, Wallenstein M. Understanding How Microbiomes Influence the Systems they Inhabit: Moving from a correlative to a causal research framework. bioRxiv 065128, doi: https://doi.org/10.1101/065128.Hall EK, Bernhardt ES, Bier RL, Bradford MA, Boot CM, Cotner JB, del Giorgio PA, Evans SE, Graham EB, Jones SE, Lennon JT, Locey KJ, Nemergut D, Osborne BB, Rocca JD, Schimel JP, Waldrop MP, Wallenstein MD. Understanding how microbiomes influence the systems they inhabit. Nature Microbiology, 2018, 3: 977–982.Hall EK, Bernhardt ES, Bier RL, Bradford MA, Boot CM, Cotner JB, del Giorgio PA, Evans SE, Graham EB, Jones SE, Lennon JT, Locey KJ, Nemergut D, Osborne BB, Rocca JD, Schimel JP, Waldrop MP, Wallenstein MD. Understanding how microbiomes influence the systems they inhabit. Nature Microbiology, 2018, 3: 977–982.Toscano M, De Grandi R, Pastorelli L, Vecchi M, Drago L. A consumer’s guide for probiotics: 10 golden rules for a correct use. Dig Liver Dis, 2017 Nov, 49(11): 1177-1184. doi: 10.1016/j.dld.2017.07.011.Toscano M, De Grandi R, Pastorelli L, Vecchi M, Drago L. A consumer’s guide for probiotics: 10 golden rules for a correct use. Dig Liver Dis, 2017 Nov, 49(11): 1177-1184. doi: 10.1016/j.dld.2017.07.011.Singh B, Mal G, Marotta F. Designer Probiotics: Paving the Way to Living Therapeutics. Trends Biotechnol, 2017 Aug, 35(8): 679-682. doi: 10.1016/j.tibtech.2017.04.001.Singh B, Mal G, Marotta F. Designer Probiotics: Paving the Way to Living Therapeutics. Trends Biotechnol, 2017 Aug, 35(8): 679-682. doi: 10.1016/j.tibtech.2017.04.001.Mansour NM, Abdelaziz SA. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen. Microbiol Immunol, 2016, 60: 527-532. doi: 10.1111/1348-0421.12397.Mansour NM, Abdelaziz SA. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen. Microbiol Immunol, 2016, 60: 527-532. doi: 10.1111/1348-0421.12397.Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon J-P, van Deventer SJH, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol, 2006, 4(6): 754-759.Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon J-P, van Deventer SJH, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol, 2006, 4(6): 754-759.Zhang B, Li A, Zuo F, Yu R, Zeng Z, Ma H, Chen S. Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells. Microb Cell Fact, 2016 Jun 10, 15(1): 102. doi: 10.1186/s12934-016- 0506-7.Zhang B, Li A, Zuo F, Yu R, Zeng Z, Ma H, Chen S. Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells. Microb Cell Fact, 2016 Jun 10, 15(1): 102. doi: 10.1186/s12934-016- 0506-7.Chua KJ, Kwok WC, Aggarwal N, Sun T, Chang MW. Designer probiotics for the prevention and treatment of human diseases. Curr Opin Chem Biol, 2017 Oct, 40: 8-16. doi: 10.1016/j.cbpa.2017.04.011.Chua KJ, Kwok WC, Aggarwal N, Sun T, Chang MW. Designer probiotics for the prevention and treatment of human diseases. Curr Opin Chem Biol, 2017 Oct, 40: 8-16. doi: 10.1016/j.cbpa.2017.04.011.Altmann F, Kosma P, O’Callaghan A, Leahy S, Bottacini F, Molloy E, Plattner S, Schiavi E, Gleinser M, Groeger D, Grant R, Rodriguez Perez N, Healy S, Svehla E, Windwarder M, Hofinger A, Motherway MO,. Akdis CF, Xu J, Roper J, van Sinderen D, O’Mahon L. Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624. PLoS ONE, 2016 Sep 22, 11(9): e0162983. doi: 10.1371/journal.pone.0162983.eCollection 2016.Altmann F, Kosma P, O’Callaghan A, Leahy S, Bottacini F, Molloy E, Plattner S, Schiavi E, Gleinser M, Groeger D, Grant R, Rodriguez Perez N, Healy S, Svehla E, Windwarder M, Hofinger A, Motherway MO,. Akdis CF, Xu J, Roper J, van Sinderen D, O’Mahon L. Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624. PLoS ONE, 2016 Sep 22, 11(9): e0162983. doi: 10.1371/journal.pone.0162983.eCollection 2016.Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes, 2013 May-Jun, 4(3): 201-11. doi: 10.4161/gmic.24196.Charbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes, 2013 May-Jun, 4(3): 201-11. doi: 10.4161/gmic.24196.Healy S, Casey M, Kiely B, Quigley EM, Shanahan F, Murphy EF. The bifidobacterium longum 35624® culture transits in high numbers through the human gut. Gut, 2017 April, 66(Suppl 1). British Society of Gastroenterology, British and Irish Gastoenterology Meeting, 27–28 April 2017, A25. http://dx.doi.org/10.1136/gutjnl-2017-314127.68.Healy S, Casey M, Kiely B, Quigley EM, Shanahan F, Murphy EF. The bifidobacterium longum 35624® culture transits in high numbers through the human gut. Gut, 2017 April, 66(Suppl 1). British Society of Gastroenterology, British and Irish Gastoenterology Meeting, 27–28 April 2017, A25. http://dx.doi.org/10.1136/gutjnl-2017-314127.68.Ren J, Ni H, Walayat S, Kim M, Balouch I, Asche CV. Efficacy of bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Value in health, 2016, 19(3): A317.Ren J, Ni H, Walayat S, Kim M, Balouch I, Asche CV. Efficacy of bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Value in health, 2016, 19(3): A317.Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Journal Current Medical Research and Opinion, 2017, 33(7): 1191-1197.Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Journal Current Medical Research and Opinion, 2017, 33(7): 1191-1197.WGO Global Guidelines. Irritable Bowel Syndrome: a Global Perspective. Update September 2015, 28 p.WGO Global Guidelines. Irritable Bowel Syndrome: a Global Perspective. Update September 2015, 28 p.World Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics. February 2017. 35 p.World Gastroenterology Organisation Global Guidelines. Probiotics and prebiotics. February 2017. 35 p.Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol, 2006 Jul, 101(7): 1581-90.Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O’Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol, 2006 Jul, 101(7): 1581-90.O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology, 2005 Mar, 128(3): 541-51.O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology, 2005 Mar, 128(3): 541-51.McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O’Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut, 2003 Jul, 52(7): 975-80.McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O’Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut, 2003 Jul, 52(7): 975-80.Charbonneau DL, Altringer LA, Carryl OR, Chen KS, Kidd KJ, Darcy T, Fawcett DH, Trowbridge MM, Jang C, Luo F, Poehner RD, Meller ST. Fecal flora effects following oral supplementation with Bifidobacteria infantis 35624 in healthy and IBS subjects. World Congress of Gastroenterology, September 2005, Montreal, Canada.Charbonneau DL, Altringer LA, Carryl OR, Chen KS, Kidd KJ, Darcy T, Fawcett DH, Trowbridge MM, Jang C, Luo F, Poehner RD, Meller ST. Fecal flora effects following oral supplementation with Bifidobacteria infantis 35624 in healthy and IBS subjects. World Congress of Gastroenterology, September 2005, Montreal, Canada.Charbonneau D, Baria M, Poehner R, Mccauleymyers D, Eads C, Furnish C, Donovanbrand R. Impact of Bifidobacterium infantis 35624 on fecal flora from healthy and IBS subjects in a chemostat model. Gastroenterology, 2005, 128: A-661.Charbonneau D, Baria M, Poehner R, Mccauleymyers D, Eads C, Furnish C, Donovanbrand R. Impact of Bifidobacterium infantis 35624 on fecal flora from healthy and IBS subjects in a chemostat model. Gastroenterology, 2005, 128: A-661.Schiavi E, Gleinser M, Molloy E, Groeger D, Frei R, Ferstl R, Rodriguez-Perez N, Ziegler M, Grant R, Moriarty TF, Plattner S, Healy S, Motherway MO, Akdis CA, Roper J, Altmann F, van Sinderen D, O’Mahonya L. The surface associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host pro-inflammatory responses and in repressing local TH17 responses. Applied and Environmental Microbiology, 2016, 82(24): 7185-7196.Schiavi E, Gleinser M, Molloy E, Groeger D, Frei R, Ferstl R, Rodriguez-Perez N, Ziegler M, Grant R, Moriarty TF, Plattner S, Healy S, Motherway MO, Akdis CA, Roper J, Altmann F, van Sinderen D, O’Mahonya L. The surface associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host pro-inflammatory responses and in repressing local TH17 responses. Applied and Environmental Microbiology, 2016, 82(24): 7185-7196.Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes, 2013 Jul-Aug, 4(4): 325-39. doi: 10.4161/gmic.25487.Groeger D, O’Mahony L, Murphy EF, Bourke JF, Dinan TG, Kiely B, Shanahan F, Quigley EM. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes, 2013 Jul-Aug, 4(4): 325-39. doi: 10.4161/gmic.25487.Ribeiro CS, van Roode MY, Haringhuizen GB, Koopmans MP, Claassen E, van de Burgwal LHM. How ownership rights over microorganisms affect infectious disease control and innovation: A root-cause analysis of barriers to data sharing as experienced by key stakeholders. PLoS One, 2018, 13(5): e0195885. doi: 10.1371/journal.pone.0195885.Ribeiro CS, van Roode MY, Haringhuizen GB, Koopmans MP, Claassen E, van de Burgwal LHM. How ownership rights over microorganisms affect infectious disease control and innovation: A root-cause analysis of barriers to data sharing as experienced by key stakeholders. PLoS One, 2018, 13(5): e0195885. doi: 10.1371/journal.pone.0195885.Moré MI, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review. Clin Exp Gastroenterol, 2015, 8: 237– 255.Moré MI, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review. Clin Exp Gastroenterol, 2015, 8: 237– 255.Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun, 2000 Oct, 68(10): 5998-6004.Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun, 2000 Oct, 68(10): 5998-6004.Pérez-Sotelo LS, Talavera-Rojas M, MonroySalazar HG, Lagunas-Bernabé S, CuarónIbargüengoytia JA, Jimenez RM, VázquezChagoyán JC. In vitro evaluation of the binding capacity of Saccharomyces cerevisiae Sc47 to adhere to the wall of Salmonella spp. Rev Latinoam Microbiol, 2005 Jul-Dec, 47(3-4): 70-5.Pérez-Sotelo LS, Talavera-Rojas M, MonroySalazar HG, Lagunas-Bernabé S, CuarónIbargüengoytia JA, Jimenez RM, VázquezChagoyán JC. In vitro evaluation of the binding capacity of Saccharomyces cerevisiae Sc47 to adhere to the wall of Salmonella spp. Rev Latinoam Microbiol, 2005 Jul-Dec, 47(3-4): 70-5.Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics – Saccharomyces boulardii. Aliment Pharmacol Ther, 2007 Sep 15, 26(6): 767-78.Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics – Saccharomyces boulardii. Aliment Pharmacol Ther, 2007 Sep 15, 26(6): 767-78.Tiago FC, Martins FS, Souza EL, Pimenta PF, Araujo HR, Castro IM, Brandão RL, Nicoli JR. Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. J Med Microbiol, 2012 Sep, 61(Pt 9): 1194-207. doi: 10.1099/ jmm.0.042283-0.Tiago FC, Martins FS, Souza EL, Pimenta PF, Araujo HR, Castro IM, Brandão RL, Nicoli JR. Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. J Med Microbiol, 2012 Sep, 61(Pt 9): 1194-207. doi: 10.1099/ jmm.0.042283-0.Pothoulakis C. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther, 2009 Oct 15, 30(8): 826-33. doi: 10.1111/j.1365-2036.2009.04102.x.Pothoulakis C. Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. Aliment Pharmacol Ther, 2009 Oct 15, 30(8): 826-33. doi: 10.1111/j.1365-2036.2009.04102.x.Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol, 2009 Apr, 156(1): 78-87. doi: 10.1111/j.1365-2249.2009.03878.x.Thomas S, Przesdzing I, Metzke D, Schmitz J, Radbruch A, Baumgart DC. Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. Clin Exp Immunol, 2009 Apr, 156(1): 78-87. doi: 10.1111/j.1365-2249.2009.03878.x.Berni Canani R, Cucchiara S, Cuomo R, Pace F, Papale F. Saccharomyces boulardii: a summary of the evidence for gastroenterology clinical practice in adults and children. Eur Rev Med Pharmacol Sci, 2011 Jul, 15(7): 809-22.Berni Canani R, Cucchiara S, Cuomo R, Pace F, Papale F. Saccharomyces boulardii: a summary of the evidence for gastroenterology clinical practice in adults and children. Eur Rev Med Pharmacol Sci, 2011 Jul, 15(7): 809-22.

The authors declare that there are no conflicts of interest present.